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Abstract
© 2018, Advanced Scientific Research. All rights reserved. In Russia, over the past 50 years, the
number  of  primary  diseases  with  colorectal  cancer  (CRC)  has  increased  7-fold;  today  in
Tatarstan every 42nd resident of the republic is registered as an oncological patient. Analysis of
patients with diagnosed rectal cancer in the RT revealed that the overall incidence of KRAS
mutations was 33%, 68% of cases with mutations in the 12th codon, 33% of the detected
mutant KRASs are homoduplexes. Patients older than 60 years carry the mutant KRAS, which
nullifies the effectiveness of Epidermal Growth Factor receptor (EFGR) inhibitors, in only 10% of
cases. In the group of patients younger than 50 years, KRAS mutations were found in 58.3% of
cases.  The  microbial  profile  of  the  biopsy  specimens  revealed  a  tendency  for  phylum
Bacteroides and Enterobacteriaceae to predominate on intact epithelium and replace them with
tumor genera Faecalibacterium, Streptococcus and Fusobacterium on tumor. The taxonomic
structure of bacterial communities of biopsy specimens is diverse; in tumor tissue, diversity can
both decrease and increase. The representation of the Prevotella genus in the epithelium with
the mutant KRAS gene was increased in 50% of cases. Expanding the spectrum of molecular
targets  in  the  epithelium  and  intestinal  microbiome  should  ensure  the  effectiveness  of
personified antitumor therapy.
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